To test this notion, we inoculated mice with KP.SIY lung or flank tumors, treated tumor-bearing mice with IL2-MSA on day 6 of tumor growth, and analyzed the ability of SIY-reactive T cells to bind IL12-MSA ex vivo on day 7 of tumor growth (Figure 2D). The gene discussed is IL2; the disease is neoplasm.